Abstract
Objective
Early recombinant erythropoietin therapy and iron therapy would decrease the need for red blood cells transfusions and prevents anemia of prematurity.
Methods
Fifty-eight preterm infants in newborn services at Ghaem Medical Center randomly were assigned, among them 18 patients were excluded. A total of 40 preterm infants with gestational age 28–34 weeks, birth weight 1000–1750 g followed the study: 20 infants in treatment group and 20 infants in control group were randomized to treatment (rhu EPO, 500u per kg, per week, 2 times weekly, subcutaneous) and control (no treatment). Therapy was initiated 4 days after birth and continued throughout the 4 weeks. All infants on enteral feeds received supplements: iron 3 mg/kg/d, vitamins and folat. Complete blood cells and reticulocyte counts were measured weekly. Transfusions and phlebotomy data were recorded. Statistical significance was determined by chi-square test, student t test and Mann-Whitney. A P value of < 0.05 was considered statistically significant.
Results
The reticulocyte counts were higher in treated infants during the study (p: 0.009). Final hematocrits were higher in treated infants (p: 0.02).The volume of packed red blood cells transfusions mililiter per infant significantly reduced (p: 0.05), the average number of transfusion per infant was also lower for treated infant than control [2 (10 % )vs 8 (40%) respectively]. No adverse effects of EPO or supplemental iron occurred.
Conclusion
The combination of early rhu EPO and iron as administered in the present study stimulated erythropoiesis and decreased red blood cells transfusion in premature infants who were 1000–1750 g at birth. The enrollments of the larger and healthier preterm infants, who are at lower risk for transfusion, are limitation of the present study.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ohls R K, The use of erythropoietin in neonates. Clin Prenatol Neonatal Hematol 2000; 27: 681–693.
Blachett V, Dror Y, Chan A. Hematology In Avery’s neonatology pathophysiology & management of the newborn. Philadeiphia, Lippincot Williams & Wilkins; 2005, 1170–1172.
Beck D, Masserey E, Meyer M, Calame A. Weekly intravenous administration of recombinant human erythropoietin in infants with the anemia of prematurity. Eur J Pediatr 1991; 150: 767–772.
Halperin Ds, Wacker P, Lacourt G. Effects of recombinant human erythropoiet in infants with the anemia of prematurity: A pilot study. J Pediatr 1990; 116: 779–786.
Halperin Ds, Wacker P, Lacourt G, Felix M, Babel J-F, Wyss M. Recombinant human erythropoietin in the treatment of infants with the anemia of prematurity. Pediatrics 2002; 110: 1253–1255.
Luchtman J, Schwartz AL, Wilson DB. The blood and hematopoietic system In Neonatal — Perinatal Medicine. Vol 2. Philadelphia; Elsevier Mosby, 2006; 1287–1356.
Donato H, Vain N, Rendo P, Vivas N, Prudent L, Larguia M et al. Effect of early versus late administration of recombinant human erythropoietin on transfusion requirements in premature Infants. Pediatrcs 2000; 105: 1066–1072.
Shanon KM, Mentzer WC, Abels RI, Wertz M, Moriyama JT, Yili W et al. Enhancement of erythropoiesis by recombinant human erythropoietin in low birth weight infants. J Pediatr 1992; 4: 586–592.
Ohlsson A, Aher SM. Early erythropoietin for preventing red blood cell transfusion in preterm and / or low birth weight infants. Cochrane Database of Systemic Review 2007; issue 1.
Maier R F, Obladen M, Sgigalla P, Inderkamp O, Duc G, Hieronimi G et al. The effect of epoetin beta recombinant human erythropoietin on the need for transfusion in low birth weight infants. N Engl J 1994; 330: 1173–1178.
Sandra JUUL. Recombinant erythropoietin as neuroprotective treatment. Clin Prenatol 2004: 129–142.
Carnielli V, Montini G, Dariol R et al. Effect of high dose of Recombinant human erythropoietin on the need for blood transfusion in preterm infants. Pediatrics 1992; 121: 98–102.
Whitehall J S, Patole S K and Campbell. Recombinant human erythropoietin in anemia of prematurity. Indian Pediatr 1999; 36: 17–27.
Strauss R G. Controversies in the management of the anemia of prematurity using single-donor red blood cell transfusions and / or recombinant human erythropoietin. Transfus Med Rev 2006; 20: 34–44.
Britton JR, Christensen RD. Enteral administration of recombinant erythropoietin to preterm infants. J Perinatol 1995; 15: 281–283.
Ohls RK, Ehrenkranz RA, Wright LL, Lemons JA, Korones S, Stoll BJ et al. Effects of early EPO therapy on the transfusion requirements of preterm infants below 1250 g birth weight. Pediatrics 2001; 108: 934–942.
Shanon KM, Keith JF, Mentzer WC, Ehrenkranz RA, Brown MS, Widness JA et al. Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocytes transfusions in very low birth weight preterm infants. Pediatrics 1995; 85: 1–8.
MP, Meyer JH, Commerford A, Hann FM, Sive AA, Moller G et al. Recombinant human erythropoietin in the treatment of the anemia of prematurity. Pediatrics 1994; 93: 918–923.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Khatami, S.F., Mamouri, G. & Torkaman, M. Effects of early human recombinant erythropoietin therapy on the transfusion in healthy preterm infants. Indian J Pediatr 75, 1227–1230 (2008). https://doi.org/10.1007/s12098-008-0225-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12098-008-0225-0